

# STANDARD TREATMENT WORKFLOW (STW)

## KAWASAKI DISEASE

Krishna Kumar<sup>1</sup>, Saurabh Gupta<sup>2</sup>, Shreepal Jain<sup>3</sup>, Ritchie Sharon Solomon<sup>4</sup>, Navaneetha Sasikumar<sup>5</sup>, Debashree Ganguly<sup>6</sup>

<sup>1</sup>Amrita Institute of Medical Sciences, Kochi, Kerala; <sup>2</sup>All India Institute of Medical Sciences Delhi; <sup>3</sup>Wadia Children's Hospital, Mumbai; <sup>4</sup>Institute of Child Health, Chennai; <sup>5</sup>Amrita Institute of Medical Sciences, Kochi, Kerala; <sup>6</sup>RN Tagore Hospital, Kolkata, West Bengal

### CORRESPONDING AUTHOR

Dr Krishna Kumar, Amrita Institute of Medical Sciences, Kochi, Kerala

Email: [kumar\\_rk@yahoo.com](mailto:kumar_rk@yahoo.com)

### CITATION

Kumar K, Gupta S, Jain S, Solomon RS, Sasikumar N, Ganguly D. KAWASAKI DISEASE Journal of the Epidemiology Foundation of India. 2024;2(2Suppl):S315-S316.


DOI: <https://doi.org/10.56450/JEFI.2024.v2i2Suppl.030>


This work is licensed under a Creative Commons Attribution 4.0 International License.

©The Author(s). 2024 Open Access

### DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.





**Standard Treatment Workflow (STW)  
KAWASAKI DISEASE**

**ICD-10-M30.3**

**Any child with fever for more than 5 days should be evaluated for KD**

**SPECIFIC SIGNS**


**A. Lips and oral cavity:**  
Erythema & Lip cracking  
Strawberry tongue and/or Diffuse erythema of oral & pharyngeal mucosa

**B. Changes in extremities:**  
Erythema of palms, soles  
Dorsal edema of hands & feet  
Periungual peeling of fingers, toes (2<sup>nd</sup> & 3<sup>rd</sup> week)

**C. Polymorphous exanthem:**  
Rash – maculopapular or erythema multiforme-like

**D. Eyes:** Bilateral conjunctival injection without exudate

**E. Cervical lymphadenopathy (>1.5cm diameter) - mostly unilateral**



**OTHER CLINICAL FINDINGS**

**GIT:** Diarrhea, vomiting, abdominal pain  
**RS:** Cough, rhinorrhea  
**CVS:** Signs of CCF, new onset murmur, gallop  
**MUSCULOSKELETAL:** Arthritis, arthralgia  
**CNS:** Extreme Irritability  
**OTHERS:** Induration at BCG scar site

**EXCLUDE OTHER COMMON DISEASES WITH SIMILAR FINDINGS**

**INFECTIONS**  
Viral: Measles, Adenovirus, Enterovirus, EBV, CMV  
Bacterial: Scarlet fever, Bacterial cervical lymphadenitis, Meningococemia, leptospirosis

**RHEUMATOLOGICAL DISEASE**  
Systemic onset juvenile idiopathic arthritis

**OTHERS**  
TSS, SSSS, Drug hypersensitivity reaction, SJS

**CONSIDER KD IN DIFFERENTIAL DIAGNOSIS IF PROLONGED FEVER OCCURS IN:**

- Infants < 6 months with irritability
- Infants with unexplained aseptic meningitis
- Infants or children with unexplained or culture –negative shock
- Infants or children with cervical lymphadenitis unresponsive to antibiotics
- Infants or children with retropharyngeal phlegmon unresponsive to antibiotics

**WHEN NOT TO CONSIDER KD?**

- Bullous/vesicular rash
- Exudative conjunctivitis
- Exudative pharyngitis
- Ulcerative oral lesions
- Generalized lymphadenopathy
- Splenomegaly

**MANAGEMENT**

INVESTIGATIONS	WHAT TO LOOK FOR?	ECHOCARDIOGRAPHY - TO BE DONE BY A PAEDIATRIC CARDIOLOGIST										
<ul style="list-style-type: none"> <li>CBC</li> <li>CRP</li> <li>ESR</li> <li>Serum electrolytes</li> <li>LFT</li> <li>Urine microscopy</li> <li>Echocardiogram</li> </ul>	<ul style="list-style-type: none"> <li>CBC: Leukocytosis –Neutrophilia, Anemia, Thrombocytosis (in 2<sup>nd</sup> week)</li> <li>CRP- ↑</li> <li>ESR- ↑</li> <li>LFT: SGOT, SGPT - ↑, Albumin ↓</li> <li>Serum electrolytes – Sodium ↓</li> <li>Urine microscopy- Sterile pyuria</li> <li>ECHO- Coronary artery dimensions, perivascular brightness, lack of tapering, LV dysfunction, mitral regurgitation, pericardial effusion</li> </ul>	<p><b>Positive ECHOCARDIOGRAM:</b></p> <ul style="list-style-type: none"> <li>Any one of the below-                             <ul style="list-style-type: none"> <li>RCA or LAD Z score: <math>\geq 2.5</math></li> <li>Coronary artery aneurysm</li> </ul> </li> <li><math>\geq 3</math> of the following: LV dysfunction, Mitral regurgitation, pericardial effusion, RCA or LAD Z score: 2 - 2.5</li> </ul> <p><b>Z-SCORE CLASSIFICATION</b></p> <table border="1" style="font-size: small;"> <tr><td>&lt; 2</td><td>Normal</td></tr> <tr><td>2-2.5</td><td>Only dilatation</td></tr> <tr><td><math>\geq 2.5</math> to &lt; 5</td><td>Small aneurysm</td></tr> <tr><td><math>\geq 5</math> to &lt; 10</td><td>Medium aneurysm</td></tr> <tr><td><math>\geq 10</math></td><td>Giant aneurysm</td></tr> </table> <p><b>2-D ECHO imaging:</b></p> <p>Aim for highest resolution &amp; frame rate possible Phased array transducer with highest frequency possible</p> <ul style="list-style-type: none"> <li>Narrow sector width</li> <li>Adjust focus to region of interest</li> <li>Reduce depth</li> <li>Zooming in</li> <li>Optimize gain</li> </ul>	< 2	Normal	2-2.5	Only dilatation	$\geq 2.5$ to < 5	Small aneurysm	$\geq 5$ to < 10	Medium aneurysm	$\geq 10$	Giant aneurysm
< 2	Normal											
2-2.5	Only dilatation											
$\geq 2.5$ to < 5	Small aneurysm											
$\geq 5$ to < 10	Medium aneurysm											
$\geq 10$	Giant aneurysm											

**TREATMENT**

- Intravenous Immunoglobulin-IVIG (2g/kg) as a single infusion over 10-12 hours
- Aspirin 80-100 mg/kg/day in 4 divided doses –till child is afebrile or 48 to 72 hrs after cessation of fever

**Aspirin: 3-5 mg/kg/day for 6 to 8 weeks**

CORONARY ARTERY	DRUG	DURATION
No involvement	Aspirin* 3-5 mg/kg/day	6-8 weeks
Only dilatation	Aspirin* 3-5 mg/kg/day	6-8 weeks
Small aneurysm	Aspirin* 3-5 mg/kg/day	Till aneurysm resolves (Consult pediatric cardiologist)
Medium aneurysm	Aspirin* 3-5 mg/kg/day + Clopidogrel 0.2-1mg/kg/day	
Giant aneurysm	Aspirin* 3-5 mg/kg/day + Anticoagulation (Warfarin: 0.2 mg/kg/day loading, then 0.1mg/kg/day or LMWH 1mg/kg/day)	

DRUGS	DOSE	DURATION
IVIG (second infusion)	2g/kg IV	Single dose
Pulse methyl prednisolone followed by Oral prednisolone in tapering doses	Intravenously (10-30 mg/kg/day)  2mg/kg	3-5 days  Till CRP is normal, then taper over 2-3 weeks
Infliximab	5mg/kg IV over 3-4 hours	Single dose

**ABBREVIATIONS**

<b>CBC:</b> Complete Blood Count	<b>KD:</b> Kawasaki Disease	<b>LV:</b> Left Ventricle	<b>SJS:</b> Stevens-Johnson Syndrome
<b>CMV:</b> Cytomegalovirus	<b>LAD:</b> Left anterior Descending Artery	<b>MAS:</b> Macrophage Activation Syndrome	<b>SSSS:</b> Staphylococcal Scalded Skin Syndrome
<b>CRP:</b> C-reactive Protein	<b>LFT:</b> Liver Function Test	<b>RCA:</b> Right coronary Artery	<b>TSS:</b> Toxic Shock Syndrome
<b>EBV:</b> Epstein-Barr Virus	<b>LMWH:</b> Low Molecular Weight Heparin	<b>SGOT:</b> Serum Glutamic Oxaloacetic Transaminase	<b>WBC:</b> White Blood Cell
<b>ESR:</b> Erythrocyte Sedimentation Rate		<b>SGPT:</b> Serum Glutamic-Pyruvic Transaminase	

**REFERENCES**

1. McCrindle BV, Sawley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Sall TT, Dahl E. American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. 2017 Apr 23;135(16):e1077-1101. doi: 10.1161/CIRC.0000000000000504. Epub 2017 Mar 20. Erratum in: *Circulation*. 2019 Jul 30;140(10):e144. doi: 10.1161/CIRC.0000000000000703. PMID: 28385648.

**⚠️ DELAY IN DIAGNOSING KAWASAKI DISEASE CAN RESULT IN ADVERSE CLINICAL OUTCOMES**

The STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of ICMR for more information: ([icmr.gov.in](http://icmr.gov.in)) for more information. ©Indian Council of Medical Research, Ministry of Health & Family Welfare, Government of India.